Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Rating of “Buy” by Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report) has been assigned an average rating of “Buy” from the fifteen analysts that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $209.1429.

Several research firms recently weighed in on PVLA. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Stephens reiterated an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. HC Wainwright reissued a “buy” rating and issued a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Finally, Truist Financial set a $207.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th.

Get Palvella Therapeutics alerts:

Check Out Our Latest Stock Analysis on Palvella Therapeutics

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System grew its holdings in shares of Palvella Therapeutics by 24,639.3% during the second quarter. California State Teachers Retirement System now owns 1,705,777 shares of the company’s stock valued at $260,677,000 after buying an additional 1,698,882 shares during the last quarter. Northwestern Mutual Wealth Management Co. purchased a new position in Palvella Therapeutics in the 2nd quarter worth approximately $35,000. Penn Capital Management Company LLC purchased a new position in Palvella Therapeutics in the 2nd quarter worth approximately $841,000. Hsbc Holdings PLC bought a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $7,641,000. Finally, Wellington Management Group LLP lifted its position in Palvella Therapeutics by 4.6% in the 2nd quarter. Wellington Management Group LLP now owns 35,594 shares of the company’s stock valued at $5,439,000 after acquiring an additional 1,554 shares in the last quarter. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $152.59 on Tuesday. Palvella Therapeutics has a one year low of $49.81 and a one year high of $161.38. The company’s 50-day simple moving average is $146.69 and its 200 day simple moving average is $127.75. The firm has a market capitalization of $2.20 billion, a P/E ratio of -31.59 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, equities research analysts expect that Palvella Therapeutics will post -6.36 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Recommended Stories

• Five stocks we like better than Palvella Therapeutics
• Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
• Insiders Are Betting Big on These 3 Healthcare Stocks
• 3 Stocks for Investors Who Still Believe Cash Is King
• Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason

Receive News & Ratings for Palvella Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palvella Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.